What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?

The preferred duration in ER+PR+/-HER2+ disease for adjuvant aromatase inhibitors is not specifically defined in guidelines separate from ER+ disease in general. An older study looking at recurrence patterns across HER2+ disease (Park et al., PMID 19956951) showed ER+HER2+ disease had more delayed r...